Open AccessHealth-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Author(s) -
Jatin J. Shah,
Sharon Shacham,
Michael Kauffman,
Patrick Daniele,
D. Tomaras,
Gabriel Tremblay,
Olivier Casasnovas,
Marie Maerevoet,
Josée M. Zijlstra,
George Follows,
Joost S.P. Vermaat,
Nagesh Kalakonda,
André Goy,
Sylvain Choquet,
Éric Van Den Neste,
Brian T. Hill,
Catherine Thiéblemont,
Federica Cavallo,
Fátima De la Cruz,
John Kuruvilla,
Nada Hamad,
Réda Bouabdallah,
Ulrich Jäger,
Paolo Caimi,
Ronit Gurion,
Krzysztof Warzocha,
Sameer Bakhshi,
Juan Manuel Sancho,
Michael W. Schuster,
Miklós Egyed,
Fritz Offner,
T. Vasilakopoulos,
Priyanka Samal,
Ágnes Nagy,
Matthew Ku,
Miguel A. Canales
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-0946
Subject(s) - medicine , quality of life (healthcare) , adverse effect , refractory (planetary science) , clinical trial , lymphoma , diffuse large b cell lymphoma , disease , oncology , physics , nursing , astrobiology
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) – Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT – Lymphoma (p ≤ 0.05), FACT – General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.